Antiemetic efficacy of aripiprazole combined with omeprazole in patients with lung cancer receiving chemotherapy

Liang Dan; Song Yang-yang; Wang Jian

doi:10.3969/j.issn.1672-8157.2025.01.039

Abstract：Objective To explore the antiemetic efficacy of aripiprazole combined with omeprazole in patients with lung cancer undergoing chemotherapy.Methods A retrospective analysis was conducted on 90 non-small cell lung cancer patients un-dergoing chemotherapy in the Department of Oncology of Shangyu People's Hospital and the Department of Oncology of Xinchang County Hospital of Traditional Chinese Medicine from June 2021 to June 2024.According to the different antiemetic treatment plans,43 cases were included in the control group(aripiprazole,dexamethasone,ondansetron)and other 47 were included in the observa-tion group(omeprazole,aripiprazole,dexamethasone,ondansetron).The complete remission rate of nausea and vomiting,functional living index-emesis(FLIE)scores and adverse reaction occurrence were compared between the two groups after treatment.Results The complete remission rates of nausea and vomiting duration,the entire course and the delay phase in the observation group were 83.72%(36/43)and 86.05%(37/43),respectively,which were higher than those of 62.50%(25/40)and 67.50%(27/40)in the control(χ2=4.791,4.038,both P<0.05).The complete remission rates of nausea and vomiting in the acute phase for the observation group and the control group were 88.37%(38/43)and 85.00%(34/40),respectively,showing no statistically significant difference between the two groups(χ2=0.205,P=0.651).The FLIE nausea subscale scores on day 3 and day 5 after chemotherapy in the observation group were(44.33±3.67)and(47.54±5.23),respectively,both of which were higher than those of(40.77±3.82)and(43.68±4.95)in the control(t=4.508,3.588,both P<0.05).The FLIE vomiting subscale scores in the observation group were(45.51±3.93)and(50.35±5.67),respectively,both of which were higher than those of(41.82±3.99)and(44.75±5.15)in the control(t=4.417,4.889,both P<0.05).There was no statistically significant difference in the incidence of dizziness,fatigue,constipation and hiccups between the two groups(P>0.05).The incidence of gastrointestinal dysfunction and decreased appetite in the observation group were 29.79%(14/47)and 25.53%(12/47),respectively,which were higher than those of 11.63%(5/43)and 9.30%(4/43)in the control(χ2=4.446,4.046,both P<0.05).Conclusion Aripiprazole combined with omeprazole can better alleviate nausea and vomiting in patients with lung cancer receiving chemotherapy,but it is necessary to monitor the concentration of omeprazole to reduce the occurrence of adverse reactions.